(Bloomberg) -- Roche Holding AG said an experimental breast-cancer treatment will get an expedited review from US regulators ... based on research showing the medicine, called inavolisib, could ...

Swiss pharma company Roche ... FDA Priority Review status for a Perjeta (pertuzumab) regimen to be used before surgery (neoadjuvant treatment) in people with HER2-positive early stage breast cancer.

The US Food and Drug Administration (FDA) has granted Roche a breakthrough therapy designation for its breast cancer therapy inavolisib ... the evaluation and review processes for certain therapies.

Get our list of 10 overlooked stocks—including one paying a 9% dividend—before Wall Street catches on. Roche Holdings AG ... (HER2)-positive early-stage breast cancer. After ten years, the ...

Roche’s Perjeta (pertuzumab)-based regimen has demonstrated sustained survival benefits in patients with early-stage breast cancer, according to new results from a long-term study of the drug. The ...

Foundation Medicine has developed the capability for high-throughput NGS analysis of genomic alterations covering more than 300 cancer ... for two Roche molecules, approved by the FDA and EMA ...